-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F7r0lgrDAAGurb69M5ORoZDdi6hTCq5+DDkS8f3lD9kV34rE88vGAEKvc7nZ8PV1 OK4dNZHW+NlMxfdjN9cxIA== 0001259870-03-000002.txt : 20031231 0001259870-03-000002.hdr.sgml : 20031231 20031231175243 ACCESSION NUMBER: 0001259870-03-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20031229 FILED AS OF DATE: 20031231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECH TARGET N V CENTRAL INDEX KEY: 0001259870 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30369 FILM NUMBER: 031080992 MAIL ADDRESS: STREET 1: DE RUYTERKADE 62 WILLEMSTAD CITY: CURACO STATE: P8 ZIP: 000000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VIROLOGIC INC CENTRAL INDEX KEY: 0001094961 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943234479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.635.1100 MAIL ADDRESS: STREET 1: 345 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30369 FILM NUMBER: 031080991 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 4 1 primary_doc.xml PRIMARY DOCUMENT X0201 4 2003-12-29 0 0001094961 VIROLOGIC INC VLGC 0001259870 BIOTECH TARGET N V DE RUYTERKADE 62 WILLEMSTAD CURACO P8 000000 NETHERLANDS ANTILLES 0 0 1 0 0000924223 BB BIOTECH AG VODERGASSE 3 SWITZERLAND SCHAFFHAUSEN V8 CH-8300 SWITZERLAND 0 0 1 0 Common Stock 2003-12-29 4 C 0 2001074 1.21 A 2001074 D Series C Convertible Preferred Stock 0 2003-12-29 4 C 0 242.13 D Common Stock 2001074 0 D Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Virologic, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V. The reporting person disclaims beneficial ownership of common stock except to the extent of any of its or its affiliates pecuniary interest therein. The reported securities were issued upon conversion of Series C Convertible Preferred Stock on December 29, 2003, at a conversion price of $1.21 per share, resulting in the acquisition of 2,001,074 shares of common stock. The Series C Convertible Preferred Stock had a face value of $10,000 per share and was convertible, subject to certain limitations, into common stock at a conversion price of $1.21 per share. Does not include 3,605,004 shares of common stock held directly by Biotech Growth, N.V., a wholly-owned subsidiary of BB Biotech AG, that may be deemed beneficially owned by Biotech Target N.V. The reported securities convert 1-for-8,264.462 Immediately Exercisable. N/A. The reported securities were issued upon conversion of a promissory note with a principal amount equal to $2,421,304.11. /s/ Adrian Bruengger, Signatory Authority for Biotech Target N.V. and BB Biotech AG 2003-12-31 EX-99 3 jointfilerinformation.txt FORM 4 JOINT FILER INFORMATION Exhibit 99 Form 4 Joint Filer Information Name: BB Biotech AG(1) Address: Vordergasse 3 8300 Schaffhausen CH/Switzerland Issuer & Ticker Symbol: Virologic, Inc. (VLGC) Date of Event Requiring Statement: 12/29/03 Signature: /s/ Adrian Bruengger Signatory Authority for Biotech Target N.V. and BB Biotech AG (1) Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Virologic Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V. -----END PRIVACY-ENHANCED MESSAGE-----